This MedLibrary.org supplementary page on Xipamide is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Xipamide
|
|
| Systematic (IUPAC) name | |
| 4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoylbenzamide | |
| Identifiers | |
| CAS number | |
| ATC code | C03 |
| PubChem | |
| Chemical data | |
| Formula | C15H15ClN2O4S |
| Mol. mass | 354.80 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Protein binding | 98% |
| Metabolism | Glucuronide (30%) |
| Half life | 5.8 to 8.2 hours |
| Excretion | Renal (1/3) and biliary (2/3) |
| Therapeutic considerations | |
| Pregnancy cat. |
Contraindication |
| Legal status | |
| Routes | Oral |
Xipamide is a sulfonamide diuretic drug marketed by Eli Lilly under the trade names Aquaphor (in Germany) and Aquaphoril (in Austria). It is used for the treatment of oedema and hypertension.
Contents |
Mechanism of action
Like the structurally related thiazide diuretics, xipamide acts on the kidneys to reduce sodium reabsorption in the distal convoluted tubule. This increases the osmolarity in the lumen, causing less water to be reabsorbed by the collecting ducts. This leads to increased urinary output. Unlike the thiazides, xipamide reaches its target from the peritubular side (blood side).1
Additionally, it increases the secretion of potassium in the distal tubule and collecting ducts. In high doses it also inhibits the enzyme carbonic anhydrase which leads to increased secretion of bicarbonate and alkalizes the urine.
Unlike with thiazides, only terminal renal failure renders xipamide ineffective.2
Uses
- cardiac oedema caused by decompensation of heart failure
- renal oedema, chronic renal disease (but not with anuria)
- hepatic oedema caused by cirrhosis
- ascites
- lymphoedema
- hypertension in combination with chronic renal disease
Pharmacokinetics
After oral administration, 20 mg of xipamide are resorbed quickly and reach the peak plasma concentration of 3 mg/l within an hour. The diuretic effect starts about an hour after administration, reaches it speak between the third and sixth hour, and lasts for nearly 24 hours.
One third of the dose is glucuronidized, the rest is excreted directly through the kidney (1/3) and the faeces (2/3). The total plasma clearence is 30-40 ml/min. Xipamide can be filtrated by haemodialysis but not by peritoneal dialysis.2
Dosage
Initially 40 mg, it can be reduced to 10-20 mg to prevent a relapse.2
The lowest effective dose is 5 mg. More than 60 mg have no additional effects.1
Adverse effects
- more than 1/10 of all patients1
- hypokalaemia, which can lead to nausea, muscular weakness or cramps, and ECG abnormities
- 1/100 to 1/10
- hyponatraemia, which can lead to headache, nausea, drowsiness or confusion
- orthostatic hypotension
- initially increase of urea, uric acid and creatinine, wchich can lead to a gout attack in predisposed patients
- 1/1000 to 1/10,000
- allergic reactions of the skin
- hyperlipidaemia
- less than 1/10,000
Contraindications
- anuria
- praecoma and coma hepaticum
- hypovolemia, hyponatremia, hypokalemia
- hypercalcemia
- gout
- sulfonamide hypersensitivity
- pregnancy, lactation period12
Interactions
Not recommended combinations
- Xipamide lowers the renal clearence of lithium which can lead to lithium intoxication.1 (This interaction is classified as medium.3)
Combinations requiring special precautions
The product information requests special precautions for these combinations:1
- The antihypertensive effect can be increased by ACE inhibitors, barbiturates, phenothiazines, tricyclic antidepressants, alcohol, etc. (Classified as minor.3)
- NSAIDs can reduce the antihypertensive and diuretic effects. Xipamide increases the neurotoxicity of high doses of salicylates. (Classified as minor.3)
- Toxicity of cardiac glycosides is increased due to hypokalemia and hypomagnesemia.(Classified as minor.3)
- Antiarrhythmic agents (classes Ia and III), phenothiazines and other antipsychotics increase the risk of torsade de pointes due to hypokalemia.
Contraindications not included in the product information
- Xipamide can reduce the effect of antidiabetics. (Classified as minor.3)
References
- ^ a b c d e f g (2007) in Jasek, W: Austria-Codex, 2007/2008 1 (in German), Vienna: Österreichischer Apothekerverlag, 600-603. ISBN 3-85200-181-4.
- ^ a b c d e (2007) in Dinnendahl, V, Fricke, U: Arzneistoff-Profile, 21 10 (in German), Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-98-46-3.
- ^ a b c d e (2007) in Klopp, T: Arzneimittel-Interaktionen, 2007/2008 (in German), Arbeitsgemeinschaft für Pharmazeutische Information. ISBN 978-3-85200-184-5.
|
||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 28 October 2008, at 20:52.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Xipamide".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.